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2Introduction: Recent guideline changes for lung cancer screening with low-
dose computed tomography recommend smoking cessation interventions be 
done in parallel with screening. The purpose of this study is to determine the
post-guideline rates of smoking cessation interventions among patients 
eligible and ineligible for lung cancer screening.
Methods: Using electronic health records collected from a large ambulatory 
care system in northern California between 2010 and 2017, authors 
identified new patients who were current smokers aged 55–80 years visiting 
a primary care provider, and grouped patients into lung cancer screening–
eligible heavy smokers, screening-ineligible moderate smokers, and 
screening-ineligible light smokers. Screening-eligible smokers versus 
screening-ineligible smokers were compared in receipt of smoking cessation 
interventions before (2010–2013) and after (2014–2017) the guideline 
change, overall and by intervention type (formal counseling, informal 
counseling, pharmacotherapy) using hierarchical generalized linear models. 
Analyses were conducted in 2018–2019.
Results: After the guideline change, the likelihood of receiving any smoking 
cessation intervention (OR=1.44, 95% CI=1.28, 1.61, p<0.05), informal 
counseling (OR=1.29, 95% CI=1.15, 1.46, p<0.05), and pharmacotherapy 
(OR=1.24, 95% CI=1.02, 1.50, p<0.05) during a new patient visit 
significantly increased, with the increase not varying by level of smoking. For
formal counseling, the post-guideline increase was greater for screening-
3eligible heavy smokers (OR=3.15, 95% CI=1.18, 8.36, p<0.05) and moderate
smokers (OR=3.58, 95% CI=1.29, 9.95, p<0.05) relative to light smokers.
Conclusions: Smoking cessation interventions increased after new lung 
cancer screening guidelines. Given the sizable adverse impacts of smoking 
on morbidity and mortality, small increases in implementation of smoking 
cessation interventions could have substantial public health benefits.
4INTRODUCTION
Despite declining rates of smoking in recent decades, smoking remains the 
leading contributor to preventable disease and death in the U.S. The Surgeon
General estimates that 87% of deaths from lung cancer are directly 
attributable to smoking.1 Further, smoking has been shown to increase the 
risk of cardiovascular disease, stroke, respiratory disease, and numerous 
cancers.2,3 With the public health impact of smoking continuing, in 2013 the 
U.S. Preventive Services Task Force (USPSTF) recommended low-dose 
computed tomography for lung cancer screening (LDCT-LCS) for current or 
recent smokers aged 55–80 years with 30 or more pack years of smoking 
history.4 In addition, the guidelines recommend smoking cessation 
interventions be done in parallel with screening.4–10
With regard to smoking cessation interventions, the USPSTF specifically 
recommends that “clinicians ask all adults about tobacco use, advise them to
stop using tobacco, and provide behavioral interventions and FDA-approved 
pharmacotherapy [(e.g., bupropion, nicotine-replacement therapy)] for 
cessation to adults who use tobacco.”11 Each approach is well established 
and has been proven individually effective,12–14 and using various combined 
approaches, such as physician counseling with pharmacotherapy, can 
increase the probability of cessation—up to 82% in one study15—versus a 
single approach.16–18 Nevertheless, reported rates of smoking cessation 
interventions by primary care providers (PCPs) vary greatly, with PCPs citing 
5lack of insurance coverage, time constraints, patient readiness to quit, and 
their own limited self-efficacy in counseling and knowledge about supporting 
therapies (e.g., behavioral interventions and medications) as barriers to 
providing smoking cessation interventions.19–22 Among smokers of all ages in 
the U.S., the number of patients reporting smoking cessation advice from 
healthcare professionals has been increasing since 2010, reaching 57.2% by 
2015. The use of cessation counseling or medication among smokers who 
were trying to quit, however, did not rise between 2010 (31.7%) and 2015 
(31.2%).23 This is concerning because more than 40% of smokers are not 
currently receiving any cessation support from healthcare professionals.
The purpose of this study is to assess the provision of smoking cessation 
interventions before (2010–2013) and after (2014–2017) the USPSTF 
recommended LDCT-LCS along with smoking cessation interventions. 
Preliminary data from the studied healthcare system show that both LDCT-
LCS orders24 and shared decision-making visits for LDCT-LCS increased after 
USPSTF guidelines. The expectation is that measures of smoking cessation 
interventions would also change. LDCT-LCS guidelines have likely: (1) 
increased the documentation of smoking history (impacting the number of 
patients considered eligible for various interventions) and (2) led to a 
renewed focus on smoking cessation. This paper compares the rate of 
change in smoking cessation interventions between LCS-eligible and -
ineligible smokers pre- and post-guideline. The authors hypothesize that all 
6cessation interventions increased after the USPSTF recommended LDCT-LCS,
with a steeper increase among LCS-eligible smokers than LCS-ineligible 
smokers.
METHODS
Study Sample
This study was a retrospective analysis using electronic health record (EHR) 
data from a large healthcare system in northern California. The analysis 
focused on patients new to the system aged 55–80 years, visiting a family 
medicine or internal medicine PCP between January 1, 2010 and December 
31, 2017, and who were identified as current smokers with no evidence of 
lung cancer based on encounter diagnosis or problem list history. The target 
age, 55–80 years, is in line with the LDCT-LCS guidelines recommendations 
from the USPSTF.4 The focus on “new patient visits” to a PCP (not necessarily
a visit for LDCT-LCS) in the healthcare system was because such visits are 
typically scheduled for a longer period of time than acute care or follow-up 
visits. Focusing just on “new patients” eliminates situations in which the PCP 
may have had previous discussions with the patient about their smoking. 
Determination of LCS eligibility requires calculation of “pack years,” defined 
as the number of packs of cigarettes smoked per day multiplied by the 
number of years the person has smoked (e.g., 1 pack-year=smoking 1 pack 
per day for 1 year). Not infrequently, the medical record for new patient 
visits with a current smoker did not contain enough information to calculate 
7pack years. Excluding those visits (n=7,184) in which eligibility for LDCT-LCS 
could not be determined owing to lack of sufficient information on smoking 
history, 63.8% of 19,862 (n=12,678) current smokers were included in the 
analysis. In addition, light smoking was defined as smoking fewer than ten 
cigarettes per day, which is consistent with the definition of light smoking in 
the Treating Tobacco Use and Dependence: 2008 Update—Clinical Practice 
Guideline.25 Current smokers were then classified as: (1) LCS-eligible heavy 
smokers (≥30 pack years), (2) LCS-ineligible moderate smokers (<30 pack 
years and ten or more cigarettes per day), and (3) LCS-ineligible light 
smokers (<30 pack years and fewer than ten cigarettes per day).
Measures
Three types of smoking cessation interventions (i.e., formal in-visit smoking 
cessation counseling, informal smoking cessation counseling or referrals to 
smoking cessation programs, and medication orders for pharmacotherapy) 
were considered. “Tobacco Cessation Counseling” is one of the quality 
metrics routinely assessed and thus is frequently noted in the EHR, but most 
such counseling does not meet the requirements for separate billing. An 
internal EHR data analyst reviewed a random sample of physician’s notes 
and confirmed that the quality metric of “Tobacco Cessation Counseling” is a
reliable indicator for in-visit smoking cessation counseling. Keyword searches
included, but were not limited to, smoking cessation and tobacco counseling 
in the procedure description. Sessions of 3–10 minutes or >10 minutes (e.g., 
8billing codes: 99406, G0375, G0376; 99407, G0436, G0437) were classified 
as “formal in-visit smoking cessation counseling.” Smoking cessation 
counseling <3 minutes is not separately billed; such unbilled in-visit smoking
cessation counseling, along with referrals for internal free smoking cessation 
programs, are categorized as “informal smoking cessation counseling or 
referrals to smoking cessation programs.” Pharmacotherapy using smoking 
deterrents was identified by a prescription order for smoking cessation 
medication, (e.g., bupropion HCL, varenicline tartrate, nicotine polacrilex).
The two key explanatory variables are “guideline change” (pre-guideline: 
2010–2013 and post-guideline: 2014–2017) and “level of smoking” (1=LCS-
eligible heavy smoker, 2=LCS-ineligible moderate smoker, 3=LCS-ineligible 
light smoker). In a supplemental analysis, the authors linked “Receiving 
LDCT-LCS referral at the same visit (yes/no)” to smoking cessation 
interventions.
Statistical Analysis
First, patient demographic, smoking history, and smoking cessation 
intervention variables by time and level of smoking were compared using 
ANOVA for continuous variables or Pearson’s chi-square test for categorical 
variables. Next, for each of the three groups, the percentage who received 
each of the smoking cessation interventions before (2010–2013) and after 
(2014–2017) guideline implementation was compared using Pearson’s chi-
9square test. Annual rates of cessation interventions for LCS-eligible smokers 
versus the two groups of LCS-ineligible smokers were plotted for comparison.
The authors also examined the association between guideline change, level 
of smoking, and smoking cessation intervention, employing hierarchical 
generalized linear models where patients (Level 1) were nested within PCP 
(Level 2) controlling for patient demographics (age, sex, race/ethnicity) 
(Model A). Next, an interaction term for guideline change and level of 
smoking was added to assess differential rates of change in smoking 
cessation intervention based on level of smoking (Model B). The same set of 
models were built for each outcome using either LCS-ineligible light smokers 
or LCS-ineligible moderate smokers as the reference group to compare LCS-
eligible heavy smokers with each of the other levels. In the supplemental 
analysis, the authors examined the association between guideline change, 
receiving LDCT-LCS referral, and smoking cessation interventions, employing
plot charts and hierarchical generalized linear models where patients (Level 
1) were nested within PCP (Level 2) controlling for patient demographics 
(age, sex, race/ethnicity). All analyses were conducted in 2018 and 2019, 
and performed using SAS, version 9.4. This work was reviewed and approved
by the Sutter Health Institutional Review Board and granted a Waiver of 
Health Insurance Portability and Accountability Act Authorization and a 
Waiver of Consent as a data-only study.
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RESULTS
The study population was primarily non-Hispanic white (71%) and female 
(52%). Roughly 61% were aged 55–64 years and 33% aged 65–74 years 
(Table 1). Forty-two percent were moderate smokers; of the remainder, LCS-
eligible heavy smokers (36%) were more prevalent than LCS-ineligible light 
smokers (21%) (Table 1). Consistent with nationwide trends,26 there was a 
general downward trend in the proportion of heavy smokers (39% to 35%) 
and an upward trend in the proportion of light smokers (19% to 23%). 
Overall, 0.2% received LDCT-LCS referrals pre-guideline versus 2.7% post-
guideline (p<0.0001), and 31% received some smoking cessation 
interventions pre-guideline versus 33% post-guideline (p<0.05) (Table 1). By 
intervention type, there was an increase from pre- to post-guideline in formal
smoking cessation counseling (0.9% to 2.7%, p<0.0001) and medication 
orders for pharmacotherapy (4.3% to 5.2%, p<0.05).
Comparing the patient characteristics across level of smoking (Appendix 
Table 1), the light smoker group had a higher proportion of individuals who 
were younger (p<0.0001), female (p<0.0001), and of racial/ethnic minorities
(p<0.0001) than heavy smokers. More than one third (36%) of heavy 
smokers smoked 40–49 pack years, slightly more than half (53%) of 
moderate smokers smoked <20 pack years, and 67% of light smokers 
smoked <10 pack years. The average pack years for heavy, moderate, and 
light smokers was 48.3 (SD=23.1), 16.9 (SD=6.8), and 7.1 (SD=4.4), 
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respectively. From 2010 to 2017, LDCT-LCS orders were received by 2.7% of 
LCS-eligible heavy smokers, 1.1% of LCS-ineligible moderate smokers, and 
0.8% of LCS-ineligible light smokers. Overall, 32% of all smokers received 
some cessation interventions, 27% received informal smoking cessation 
counseling or referrals to smoking cessation programs, 1.9% received formal
smoking cessation counseling, and 4.8% received pharmacotherapy. The 
proportion of heavy smokers with pharmacotherapy was significantly higher 
than that of light smokers (p<0.0001). There was no significant difference in 
proportion of smokers receiving other types of intervention or any type of 
intervention across three groups.
As shown in Table 2, the proportion of smokers receiving any smoking 
cessation intervention increased post-guideline: LCS-eligible heavy smokers 
(30.1% to 34%), moderate smokers (31.1% to 31.4%), and light smokers 
(30.4% to 33.4%). The types of intervention, however, differed across 
smoking category. The proportion of smokers receiving formal smoking 
counseling increased nearly fourfold (from lower base rates) among both 
heavy smokers (0.9% to 3.4%, p<0.0001) and moderate smokers (0.6% to 
2.6%, p<0.0001) versus a smaller increase among light smokers (1.5% to 
2.1%, p=0.29853). Informal smoking cessation counseling—by far the most 
common intervention—was essentially flat for heavy and moderate smokers, 
but increased from 26.4% to 29.1% among the light smokers, although not 
statistically significant (p=0.13137). Heavy smokers had the highest base 
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rates and increases for medication prescriptions (5.2% to 6.9%, p=0.01902); 
moderate smokers also saw a small increase (3.5% to 4.7%, p=0.03889), but
there was a decrease for light smokers (4.0% to 3.8%, p=0.8485). Figure 1 
depicts the annual trends among new patients by level of smoking in 
percentages receiving smoking cessation interventions. There was 
prominent fluctuation in unbilled, informal counseling among light smokers 
relative to heavy and moderate smokers. The proportion of heavy smokers 
receiving formal smoking counseling has been increasing since 2010 and it 
accelerated after 2015. The moderate smoker group rate also picked up after
2016. There was a downward trend in cessation medication prescriptions for 
heavy smokers until 2013, then a reversal to an upward trend. The reverse 
appeared for light smokers—an upward trend until 2013, then roughly flat. 
Moderate smokers exhibited no discernable trend.
After controlling for age, sex, race/ethnicity, and level of smoking, there were
significant increases after the guideline change in the likelihood of receiving 
any smoking cessation intervention (OR=1.44, 95% CI=1.28, 1.61, p<0.05), 
informal counseling (OR=1.29, 95% CI=1.15, 1.46, p<0.05), and 
pharmacotherapy (OR=1.24, 95% CI=1.02, 1.50, p<0.05). There was no 
difference, however, in the trend based on smoking level (Table 3). For 
formal counseling, the post-guideline increase was greater (indicated by the 
interaction between guideline change and level of smoking) for LCS-eligible 
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heavy smokers (OR=3.15, 95% CI=1.18, 8.36, p<0.05) and moderate 
smokers (OR=3.58, 95% CI=1.29, 9.95, p<0.05) than light smokers.
As shown in Appendix Figure 1 and Appendix Table 2, the smokers that were 
newly seen by a PCP and who received a referral for LDCT-LCS at the same 
visit were more likely to receive informal counseling (OR=1.52, 95% 
CI=1.08, 2.14, p<0.05), formal counseling (OR=3.58, 95% CI=1.68, 7.61, 
p<0.05), pharmacotherapy (OR=3.17, 95% CI=2.06, 4.9, p<0.05), and any 
smoking cessation intervention (OR=2.26, 95% CI=1.63, 3.12, p<0.05), 
controlling for time, age, sex, and race/ethnicity. Note that Hispanic patients 
were less likely than non-Hispanic whites to receive formal counseling 
(OR=0.54, 95% CI=0.3, 0.95, p<0.05) and non-Hispanic Asians were less 
likely than non-Hispanic whites to receive medication orders for 
pharmacotherapy (OR=0.51, 95% CI=0.33, 0.81, p<0.05), controlling for all 
other factors.
DISCUSSION
This study is among the first to examine the implementation of smoking 
cessation interventions by level of smoking among older patients after the 
new LDCT-LCS guidelines in 2013. The likelihood of receiving any smoking 
cessation intervention significantly increased after 2013, irrespective of level
of smoking. The differential change by level of smoking was more 
pronounced for formal smoking cessation counseling during a visit. For heavy
14
and moderate smokers, formal cessation counseling rates increased more 
than fourfold after the guideline implementation versus a smaller increase 
for light smokers.
When the LDCT-LCS program started in 2013, presentations for PCPs at all 
the major clinic sites in the healthcare system reviewed the results of 
National Lung Screening Trial27 and the guidelines, and discussed the need 
for shared decision making and patient selection as well as smoking 
cessation and appropriate follow-up per Lung CT Screening Reporting & Data
System (Lung-RADS). However, LDCT-LCS is a complex process including 
multiple components and carries potential risks,27,28 so the implementation of
LDCT-LCS faces barriers at patient,29,30 provider,31–36 and healthcare system 
levels.37 Therefore, awareness of the new LDCT-LCS guidelines may not 
necessarily have led to LDCT-LCS screening in specific cases, but may have 
led to an increased cessation effort on the part of physicians. For coverage of
LDCT-LCS, Medicare requires smoking cessation interventions be performed 
in conjunction with screening.10 The LDCT-LCS rate was steadily increasing, 
but was far lower than the incidence of cessation interventions.24
The temporal change in smoking cessation intervention incidence observed 
in this study may also be attributable to factors beyond the LDCT-LCS 
guideline implementation. One potential contributor is the re-released 
USPSTF recommendation in 2015 for clinicians to offer cessation support to 
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smokers.11 This, however, is less likely to have a “differential” impact by 
level of smoking. Other than the presentations associated with the LDCT-LCS
guideline recommendations in 2013, there were no efforts in the healthcare 
system specifically targeting tobacco treatment during 2010–2017. Thus, the
implementation of the screening guideline is a plausible explanation for the 
observed differential trend in smoking cessation intervention based on level 
of smoking. Furthermore, the supplemental study results indicate that there 
are positive relationships between LDCT-LCS referral and smoking cessation 
interventions.
It is well established that healthcare providers should play a key role in 
fighting tobacco use.14 Previous work has shown more than 80% of smokers 
visit a PCP each year,38 and physician advice has been estimated to increase 
cessation rates by about 30%.39 With more than 65% of smokers having 
expressed an interest in quitting,23,40 if, as a result of physician advice, those 
smokers try to quit and even a small percentage succeed in complete 
abstinence,14 this may decrease morbidity and mortality among smokers and
the public health burden of smoking.41 Recommendations have pointed out 
the importance of providing smoking cessation interventions specifically 
within the context of the LDCT-LCS environment.42,43
Importantly, this work focused on older smokers who meet the age criteria of
55–80 years for LDCT-LCS. The 2015 National Health Interview Survey 
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indicates that older smokers have less interest in quitting smoking and 
report fewer past-year quit attempts than younger smokers.23 Thus, the 
lower rates of smoking cessation interventions among current smokers aged 
55–80 years23 may reflect “hard-to-convince” long-time smokers who are 
unable or unwilling to participate in smoking cessation interventions.42,44,45 
However challenging, the effort is worthwhile—older adults are more likely to
have aging-related medical illnesses that may be exacerbated by smoking.1 
Previous reviews have suggested that the older smokers respond to smoking
cessation interventions at similar rates to younger smokers and that 
cessation brings health benefits.46,47 The observed increase, albeit small 
(from 31% to 33%), in smoking cessation interventions among smokers aged
55–80 years during new patient visits after the guideline change is 
encouraging. Moreover, there was a statistically significant increase in formal
smoking cessation counseling and medication orders for pharmacotherapy. 
Both receipt of intensive smoking cessation counseling and 
pharmacotherapy can improve quit rates12–14 and this finding in older 
smokers is particularly important.
Limitations
The authors recognize several limitations. First, the data come from a single 
healthcare organization whose primary care base reflects a relatively well-
insured patient population. However, the organization covers a substantial 
geographic area that includes low-income, rural, non-English speaking, and 
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minority patients reflecting the population of California. Second, EHR 
structured fields may not have captured all informal counseling sessions and 
referrals. Additionally, many smoking cessation medications can be 
purchased over the counter without prescription, so those obtaining these 
medications on their own may not be recorded in the EHR. Third, it was not 
possible to distinguish the effects of the guidelines per se from other time-
related factors (e.g., the re-released USPSTF recommendation for smoking 
cessation in 201511) that may lead to increased smoking cessation 
interventions over time. However, no other factors have been found to 
explain the differential effects by level of smoking. The LDCT-LCS guideline 
that focuses on heavy smokers is a plausible explanation for the steeper rise 
in formal counseling among LCS-eligible heavy smokers than LCS-ineligible 
light smokers.
CONCLUSIONS
Discussing LDCT-LCS may provide a teachable moment to promote tobacco 
cessation.48,49 The findings of this study highlight how the requirement to 
integrate smoking cessation interventions as part of the LDCT-LCS process 
may have improved physician-administered cessation efforts more broadly. 
Further work should be done to examine the mechanism(s) through which 
this happened and whether these increased efforts result in any measurable 
reduction in smoking rates and long-term abstinence. Given the dramatic 
benefits of smoking cessation on reducing mortality, even a modest increase
18
in implementation of smoking cessation interventions and potentially modest
success of quitting after intervention would imply substantial public health 
benefits.
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among new patients by level of smoking.
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Table 1. Characteristics of New Patients (N=12,678), 55‒80 Years Old, 
Currently Smoking, 2010‒2017
Individual-level 
variables
All
(N=12,6
78)
Pre-
guideline
2010‒2013
(n=5,580)
Post-
guideline
2014‒2017
(N=7,098)
p-
value
N (%) N (%) N (%)
Age, years 0.246
06
55‒64 7,695
(60.7)
3,343 (59.9) 4,352 (61.3)
65‒74 4,183
(33.0)
1,884 (33.8) 2,299 (32.4)
75‒80 800 (6.3) 353 (6.3) 447 (6.3)
Female 6,635
(52.3)
2,977 (53.4) 3,658 (51.5) 0.042
17
Race/ethnicity 0.000
02
Missing 1,084
(8.6)
489 (8.8) 595 (8.4)
NH white 8,959
(70.7)
4,038 (72.4) 4,921 (69.3)
Hispanic 974 (7.7) 388 (7.0) 586 (8.3)
NH black 750 (5.9) 278 (5.0) 472 (6.6)
NH Asian 525 (4.1) 230 (4.1) 295 (4.2)
Other 386 (3.0) 157 (2.8) 229 (3.2)
Level of smoking <0.00
01
LCS-eligible heavy 
smokers
4,619
(36.4)
2,170 (38.9) 2,449 (34.5)
LCS-ineligible 
moderate smokers
5,346
(42.2)
2,349 (42.1) 2,997 (42.2)
LCS-ineligible light 
smokers
2,713
(21.4)
1,061 (19.0) 1,652 (23.3)
Receiving LCS-LDCT 204 (1.6) 9 (0.2) 195 (2.7) <0.00
31
referral 01
Informal smoking 
cessation counseling or 
referrals to smoking 
cessation programs
3,429
(27.0)
1,513 (27.1) 1,916 (27.0) 0.878
81
Formal smoking 
cessation counseling
243 (1.9) 49 (0.9) 194 (2.7) <0.00
01
Medication orders for 
pharmacotherapy
609 (4.8) 238 (4.3) 371 (5.2) 0.011
96
Receiving any smoking 
cessation intervention(s)
4,031
(31.8)
1,708 (30.6) 2,323 (32.7) 0.011
01
Pack-years categories <0.00
01
<10 2,536
(20.0)
1,008 (18.1) 1,528 (21.5)
10‒19 3,023
(23.8)
1,258 (22.5) 1,765 (24.9)
20‒29 2,500
(19.7)
1,144 (20.5) 1,356 (19.1)
30‒39 1,399
(11.0)
637 (11.4) 762 (10.7)
40‒49 1,639
(12.9)
769 (13.8) 870 (12.3)
50‒59 749 (5.9) 349 (6.3) 400 (5.6)
>60 832 (6.6) 415 (7.4) 417 (5.9)
Pack-years, mean (SD) 26.2
(22.6)
27.7 (23.5) 25.1 (21.7) <0.00
01
Cigarettes per day, mean
(SD)
14.7
(10.2)
15.2 (10.5) 14.2 (9.9) <0.00
01
Number of years 
smoked, mean (SD)
34.6
(13.9)
35.2 (13.9) 34.0 (13.9) <0.00
01
Note: Boldface indicates statistical significance (p<0.05).
LCS, lung cancer screening; NH, non-Hispanic; LDCT, low-dose computed 
tomography.
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Table 2. Differences in Percent Receiving Smoking cessation interventions by Level of Smoking and Time
Variable LCS-eligible heavy
smokers
LCS-ineligible
moderate smokers
LCS-ineligible light
smokers
Pre-
guideli
ne
Post-
guideli
ne
p-
value
Pre-
guideli
ne
Post-
guideli
ne
p-
value
Pre-
guideli
ne
Post-
guideli
ne
p-
value
N (%) N (%) N (%) N (%) N (%) N (%)
Informal smoking 
cessation 
counseling or 
referrals to smoking
cessation programs
568
(26.2)
649
(26.5)
0.802
1
665
(28.3)
787
(26.3)
0.094
37
280
(26.4)
480
(29.1)
0.131
37
Formal smoking 
cessation 
counseling
19
(0.9)
83
(3.4)
<0.00
01
14
(0.6)
77
(2.6)
<0.00
01
16
(1.5)
34
(2.1)
0.298
53
Medication orders 
for 
pharmacotherapy
113
(5.2)
168
(6.9)
0.019
02
83
(3.5)
140
(4.7)
0.038
89
42
(4)
63
(3.8)
0.848
5
Receiving any 
smoking cessation 
intervention(s)
654
(30.1)
832
(34)
0.005
36
731
(31.1)
940
(31.4)
0.847
85
323
(30.4)
551
(33.4)
0.113
39
Note: Boldface indicates statistical significance (p<0.05).
LCS, lung cancer screening.
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Table 3. ORs of Receiving Smoking cessation interventions Before (2010‒2013) and After (2014‒2017) 
Guideline Changea
Variable Informal smoking
cessation
counseling or
referrals to smoking
cessation programs
Formal
smoking
cessation
counseling
Medication
orders for
pharmacotherap
y
Receiving any
smoking
cessation
intervention(s)
Model Ab Model B Model
A
Model
Bb
Model
Ab
Model
B
Model
Ab
Model
B
OR
(95% CI)
OR
(95% CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
Level of smoking 
(ref=light smokers)
LCS-eligible heavy 
smokers vs LCS-
ineligible light 
smokers
0.96
(0.84, 1.1)
1.05
(0.85,
1.29)
1.81
(1.16,
2.84)
0.77
(0.34,
1.77)
1.68
(1.31,
2.16)
1.37
(0.94,
2.01)
1.09
(0.96,
1.24)
1.06
(0.87,
1.29)
LCS-ineligible 
moderate smokers 
vs LCS-ineligible 
light smokers
0.98
(0.86,
1.11)
1.17
(0.96,
1.44)
1.39
(0.89,
2.18)
0.53
(0.22,
1.28)
1.02
(0.79,
1.31)
0.79
(0.53,
1.17)
1.00
(0.88,
1.13)
1.07
(0.88,
1.30)
Guideline change
Post- vs pre-
guideline
1.29
(1.15,
1.46)
1.55
(1.24,
1.95)
5.03
(3.05,
8.30)
1.92
(0.83,
4.47)
1.24
(1.02,
1.50)
0.92
(0.60,
1.40)
1.44
(1.28,
1.61)
1.48
(1.19,
1.83)
34
Guideline change 
level of smoking
Post- vs pre-
guideline, LCS-
eligible heavy 
smokers vs LCS-
ineligible light 
smokers
0.87
(0.66,
1.14)
3.15
(1.18,
8.36)
1.39
(0.85,
2.28)
1.06
(0.82,
1.37)
Post- vs pre-
guideline, LCS-
ineligible moderate 
smokers vs LCS-
ineligible light 
smokers
0.73
(0.56,
1.01)
3.58
(1.29,
9.95)
1.51
(0.90,
2.53)
0.89
(0.69,
1.14)
Model Ab Model B Model
A
Model
Bb
Model
Ab
Model
B
Model
Ab
Model
B
OR
(95% CI)
OR
(95% CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
OR
(95%
CI)
Level of smoking 
(ref=moderate 
smokers)
LCS-eligible heavy 
smokers vs LCS-
ineligible moderate 
smokers
0.98
(0.88,
1.10)
0.89
(0.76,
1.05)
1.30
(0.91,
1.86)
1.45
(0.66,
3.20)
1.66
(1.36,
2.02)
1.75
(1.28,
2.38)
1.09
(0.98,
1.21)
0.99
(0.85,
1.15)
LCS-ineligible light 
smokers vs LCS-
ineligible moderate 
1.02
(0.90,
0.85
(0.69,
0.72
(0.46,
1.88
(0.78,
0.98
(0.76,
1.27
(0.85,
1.00
(0.89,
0.94
(0.77,
35
smokers 1.17) 1.05) 1.13) 4.50) 1.27) 1.90) 1.13) 1.14)
Guideline change
Post- vs pre-
guideline
1.29
(1.15,
1.46)
1.14
(0.96,
1.34)
5.03
(3.04,
8.30)
6.89
(3.30,
14.36)
1.24
(1.02,
1.50)
1.39
(1.02,
1.88)
1.44
(1.28,
1.61)
1.31
(1.12,
1.53)
Guideline change 
level of smoking
Post- vs pre-
guideline, LCS-
eligible heavy 
smokers vs LCS-
ineligible moderate 
smokers
1.19
(0.95,
1.48)
0.88
(0.36,
2.13)
0.92
(0.62,
1.37)
1.20
(0.97,
1.47)
Post- vs pre-
guideline, LCS-
ineligible light 
smokers vs LCS-
ineligible moderate 
smokers
1.37
(0.99,
1.77)
0.28
(0.10,
0.78)
0.66
(0.40,
1.11)
1.13
(0.88,
1.44)
Notes: Boldface indicates statistical significance (p<0.05). Model A: hierarchical generalized linear models 
where patients (Level 1) were nested within PCP (Level 2) to test main effects of guideline change and 
level of smoking. Model B added an interaction for guideline change and level of smoking to Model A to 
assess a differential change in smoking cessation intervention based on level of smoking.
aPatient demographics (age, sex, race/ethnicity) are controlled for in each model.
bFinal model.
LCS, lung cancer screening.
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1
37
Appendix Figure 1. Trends in percent of receiving smoking cessation 
interventions among new patients by receipt of lung cancer screening 
referral.
LCS, lung cancer screening.
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Appendix Table 1. Characteristics of New Patients (N=12,678), Aged 55‒80 Years, Currently Smoking by 
Level of Smoking, 2010‒2017
Individual-level variables All
(N=12,678
)
LCS-eligible
heavy
smokers
(N=4,619)
LCS-ineligible
moderate
smokers
(N=5,346)
LCS-ineligible
light smokers
(N=2,713)
p-
value
N (%) N (%) N (%) N (%)
Year <0.00
01
2010 991 (7.8) 386 (8.4) 451 (8.4) 154 (5.7)
2011 1,228 (9.7) 478 (10.3) 537 (10.0) 213 (7.9)
2012 1,461
(11.5)
577 (12.5) 596 (11.1) 288 (10.6)
2013 1,900
(15.0)
729 (15.8) 765 (14.3) 406 (15.0)
2014 2,181
(17.2)
795 (17.2) 926 (17.3) 460 (17.0)
2015 1,958
(15.4)
688 (14.9) 842 (15.8) 428 (15.8)
2016 1,647
(13.0)
537 (11.6) 681 (12.7) 429 (15.8)
2017 1,312
(10.3)
429 (9.3) 548 (10.3) 335 (12.3)
Age, years <0.00
01
39
55‒64 7,695
(60.7)
2,541 (55.0) 3,495 (65.4) 1,659 (61.2)
65‒74 4,183
(33.0)
1,700 (36.8) 1,636 (30.6) 847 (31.2)
75‒80 800 (6.3) 378 (8.2) 215 (4.0) 207 (7.6)
Female 6,635
(52.3)
2,115 (45.8) 2,902 (54.3) 1,618 (59.6) <0.00
01
Race/ethnicity <0.00
01
Missing 1,084 (8.6) 413 (8.9) 430 (8.0) 241 (8.9)
NH white 8,959
(70.7)
3,597 (77.9) 3,775 (70.6) 1,587 (58.5)
Hispanic 974 (7.7) 242 (5.2) 381 (7.1) 351 (12.9)
NH black 750 (5.9) 134 (2.9) 366 (6.8) 250 (9.2)
NH Asian 525 (4.1) 122 (2.6) 206 (3.9) 197 (7.3)
Other 386 (3.0) 111 (2.4) 188 (3.5) 87 (3.2)
LCS-LDCT order 204 (1.6) 123 (2.7) 58 (1.1) 23 (0.8) <0.00
01
Informal smoking cessation 
counseling or referrals to 
smoking cessation programs
3,429
(27.0)
1,217 (26.3) 1,452 (27.2) 760 (28.0) 0.291
79
Formal smoking cessation 
counseling
243 (1.9) 102 (2.2) 91 (1.7) 50 (1.8) 0.175
92
40
Medication orders for 
pharmacotherapy
609 (4.8) 281 (6.1) 223 (4.2) 105 (3.9) <0.00
01
Receiving any smoking 
cessation intervention(s)
4,031
(31.8)
1,486 (32.2) 1,671 (31.3) 874 (32.2) 0.538
93
Pack-years categories <0.00
01
<10 2,536
(20.0)
0 (0) 725 (13.6) 1,811 (66.8)
10‒19 3,023
(23.8)
0 (0) 2,128 (39.8) 895 (33.0)
20‒29 2,500
(19.7)
0 (0) 2,493 (46.6) 7 (0.3)
30‒39 1,399
(11.0)
1,399 (30.3) 0 (0) 0 (0)
40‒49 1,639
(12.9)
1,639 (35.5) 0 (0) 0 (0)
50‒59 749 (5.9) 749 (16.2) 0 (0) 0 (0)
>60 832 (6.6) 832 (18.0) 0 (0) 0 (0)
Pack-years, mean (SD) 26.2 (22.6) 48.3 (23.1) 16.9 (6.8) 7.1 (4.4) <0.00
01
Cigarettes per day, mean 
(SD)
14.7 (10.2) 23.3 (10.5) 12.3 (5.3) 4.5 (1.6) <0.00
01
Number of years smoked, 
mean (SD)
34.6 (13.9) 42.1 (9.2) 30.0 (13.7) 30.7 (15.5) <0.00
01
Note: Boldface indicates statistical significance (p<0.05).
41
LCS, lung cancer screening; NH, non-Hispanic; LDCT, low-dose computed tomography.
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Appendix Table 2. ORs of Receiving Smoking cessation interventions Between New Smokers Who 
Received Lung Cancer Screening Referral and Those Who Did Nota
Effect Informal smoking
cessation counseling
or referrals to
smoking cessation
programs
Formal
smoking
cessation
counseling
Medication
orders for
pharmacotherapy
Receiving any
smoking
cessation
intervention(s)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Receive LCS 
referral
Yes vs no 1.52 (1.08, 2.14) 3.58 (1.68,
7.61)
3.17 (2.06, 4.9) 2.26 (1.63, 3.12)
Guideline change
Post- vs pre-
guideline
1.35 (1.22, 1.49) 4.51 (2.98,
6.84)
1.13 (0.96, 1.34) 1.44 (1.31, 1.58)
Sex
Female vs male 1.03 (0.95, 1.12) 1.22 (0.92,
1.61)
1.11 (0.95, 1.29) 1.05 (0.97, 1.13)
Age group
55‒64 vs 75‒80 
years
1.24 (1.05, 1.47) 0.60 (0.34,
1.04)
2.63 (1.67, 4.15) 1.28 (1.09, 1.5)
65‒74 vs 75‒80 
years
1.14 (0.96, 1.37) 0.85 (0.48,
1.51)
1.97 (1.23, 3.15) 1.18 (1.00, 1.4)
Race/ethnicity
Hispanic vs white 0.99 (0.86, 1.14) 0.54 (0.30, 0.96 (0.74, 1.26) 0.95 (0.83, 1.08)
43
0.95)
Black vs white 0.89 (0.75, 1.05) 0.94 (0.54,
1.63)
1.16 (0.87, 1.54) 0.92 (0.79, 1.07)
Asian vs white 1.04 (0.86, 1.25) 1.32 (0.69,
2.54)
0.51 (0.33, 0.81) 0.98 (0.82, 1.17)
Other vs white 1.05 (0.86, 1.29) 2.07 (0.98,
4.38)
0.68 (0.42, 1.08) 1.4 (0.85, 1.26)
Note: Boldface indicates statistical significance (p<0.05).
aPatient demographics (age, sex, race/ethnicity) are controlled for in each model.
LCS, lung cancer screening.
